| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Safety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaNCT05184335 | Reviva Pharmaceuticals | Phase 3 | Recruiting | 2025-02Estimated |
| A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With VolanesorsenNCT05185843 | IONS | Phase 3 | Active not recruiting | 2027-06Estimated |
| (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisNCT05186753 | COGT | Phase 2 | Active not recruiting | 2025-05-22Actual |
| Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCMNCT05186818 | Cytokinetics | Phase 3 | Completed | 2023-11-10Actual |
| Open-Label Proof of Concept Study of VP-315 in Basal Cell CarcinomaNCT05188729 | VRCA | Phase 2 | Completed | 2024-04-15Actual |
| Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayNCT05194124 | RYTM | Phase 3 | Completed | 2023-10-19Actual |
| A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)NCT05195528 | PHAT | Phase 3 | Completed | 2022-11-21Actual |
| Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase InhibitorNCT05198310 | Kiniksa Pharmaceuticals, Ltd. | Phase 2 | Completed | 2024-02-08Actual |
| Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept TrialNCT05200936 | Definium Therapeutics US, Inc. | Phase 2 | Completed | 2023-11-06Actual |
| A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry EyeNCT05201170 | PTN | Phase 3 | Completed | 2023-09-01Actual |
| Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 CirrhosisNCT05201404 | Can-Fite BioPharma | Phase 3 | Recruiting | 2026-02Estimated |
| Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05201638 | Immunic AG | Phase 3 | Active not recruiting | 2026-11Estimated |
| A Second Study of Cytisinicline for Smoking Cessation in Adult SmokersNCT05206370 | Achieve Life Sciences | Phase 3 | Completed | 2023-03-21Actual |
| (Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal TumorsNCT05208047 | COGT | Phase 3 | Recruiting | 2025-09-30Actual |
| THIO Sequenced With Cemiplimab in Advanced NSCLCNCT05208944 | Maia Biotechnology | Phase 2 | Active not recruiting | 2027-09-30Estimated |
| A Study of Rusfertide in Adults With Polycythemia Vera (PV)NCT05210790 | PTGX | Phase 3 | Active not recruiting | 2025-02-21Actual |
| Study to Evaluate ARD-101 in Adults Receiving Bariatric SurgeryNCT05215847 | AARD | Phase 2 | Completed | 2023-02-03Actual |
| ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)NCT05216224 | ACRS | Phase 2 | Completed | 2022-12-23Actual |
| Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)NCT05217667 | Arrowhead Pharmaceuticals | Phase 2 | Terminated | 2023-05-02Actual |
| A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial DiseaseNCT05218655 | PTC Therapeutics | Phase 3 | Completed | 2025-04-15Actual |
| Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy BodiesNCT05225415 | Cognition Therapeutics | Phase 2 | Completed | 2024-11-25Actual |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsNCT05232916 | GLSI | Phase 3 | Recruiting | 2031-12Estimated |
| Lomecel-B Effects on Alzheimer's DiseaseNCT05233774 | LGVN | Phase 2 | Completed | 2023-09-29Actual |
| The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic ConjunctivitisNCT05234554 | ALDX | Phase 3 | Completed | 2023-04-22Actual |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNCT05243550 | URGN | Phase 3 | Active not recruiting | 2023-04-26Actual |
| Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt DiseaseNCT05244304 | BLTE | Phase 3 | Completed | 2025-08-04Actual |
| 4D-710 in Adult Patients With Cystic FibrosisNCT05248230 | 4D Molecular Therapeutics | Phase 2 | Recruiting | 2027-06Estimated |
| Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR MutationsNCT05256290 | BDTX | Phase 1, Phase 2 | Recruiting | 2028-03Estimated |
| Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerNCT05257408 | Corcept Therapeutics | Phase 3 | Active not recruiting | 2025-03-31Actual |
| A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)NCT05263999 | Equillium | Phase 3 | Terminated | 2025-04-22Actual |
Trial details
- Registry ID
- NCT05184335
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05185843
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05186753
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05186818
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05188729
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05194124
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05195528
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05198310
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05200936
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05201170
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05201404
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05201638
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05206370
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05208047
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05208944
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05210790
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05215847
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05216224
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05217667
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05218655
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05225415
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05232916
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05233774
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05234554
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05243550
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05244304
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05248230
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05256290
- Phase
- Phase 1, Phase 2
Trial details
- Registry ID
- NCT05257408
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05263999
- Phase
- Phase 3
Primary completion marks the end of data collection for the main study measures, not a results publication date.